Lepu Biopharma (SEHK:2157) Rebound Puts Its Valuation Back In Focus

Simply Wall St.07-08

Lepu Biopharma (SEHK:2157) stock has been moving without a clear headline catalyst, leaving investors to focus on its recent price swings, revenue profile and ongoing oncology drug portfolio when ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649633957?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-07-08 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649633957","market":"nz","top_or_hot":-1,"title":"Lepu Biopharma (SEHK:2157) Rebound Puts Its Valuation Back In Focus","media":"Simply Wall St.","content":"<div>\n<p>Lepu Biopharma (SEHK:2157) stock has been moving without a clear headline catalyst, leaving investors to focus on its recent price swings, revenue profile and ongoing oncology drug portfolio when ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-rebound-puts-its-valuation-back-in-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lepu Biopharma (SEHK:2157) Rebound Puts Its Valuation Back In Focus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLepu Biopharma (SEHK:2157) Rebound Puts Its Valuation Back In Focus\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-08 09:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-rebound-puts-its-valuation-back-in-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lepu Biopharma (SEHK:2157) stock has been moving without a clear headline catalyst, leaving investors to focus on its recent price swings, revenue profile and ongoing oncology drug portfolio when ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-rebound-puts-its-valuation-back-in-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-rebound-puts-its-valuation-back-in-f","article_id":"2649633957","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-rebound-puts-its-valuation-back-in-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2649633957","pubTimestamp":1783474335,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Lepu Biopharma (SEHK:2157) stock has been moving without a clear headline catalyst, leaving investors to focus on its recent price swings, revenue profile and ongoing oncology drug portfolio when assessing the shares.\nSee our latest analysis for Lepu Biopharma.\nThe latest move leaves Lepu Biopharma trading at HK$4.3, after a 1 week share price return of about 11% and a 1 month gain of roughly 12%. However, the weaker 3 month and 1 year total shareholder returns indicate that momentum has been...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02157":"乐普生物"},"translate_title":"乐普生物(SEHK：2157)反弹使其估值重新成为焦点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":0.9},"content_text":"Lepu Biopharma (SEHK:2157) stock has been moving without a clear headline catalyst, leaving investors to focus on its recent price swings, revenue profile and ongoing oncology drug portfolio when assessing the shares. See our latest analysis for Lepu Biopharma. The latest move leaves Lepu Biopharma trading at HK$4.3, after a 1 week share price return of about 11% and a 1 month gain of roughly 12%. However, the weaker 3 month and 1 year total shareholder returns indicate that momentum has been fading over a longer stretch. If you are comparing Lepu Biopharma with other potential ideas in oncology and drug development, it can be useful to see what else is on the move in similar areas through the 131 healthcare AI stocks Given Lepu Biopharma’s recent rebound but softer longer term returns, the issue now is whether this is an early reset that justifies stepping in, or if waiting for a different entry price makes more sense as the valuation picture is unpacked next. AdvertisementPreferred P/E Multiple of 25.7x: Is it justified? Lepu Biopharma is trading at HK$4.3 on a P/E of 25.7x, which places the stock below both its Asian biotech peers and the broader peer group on this metric. The P/E multiple compares the current share price with earnings per share, so it reflects what investors are currently paying for each unit of profit. For a biopharma company that has only recently become profitable, this can be a useful shorthand for how the market is treating its earnings profile. Here, Lepu Biopharma’s P/E of 25.7x sits below the Asian biotech industry average of 31.6x and below the peer average of 44x. That gap suggests the market is valuing its earnings at a lower level than comparable stocks, even though the company has moved into profit and is running a portfolio of late stage oncology candidates. For investors weighing up whether that discount is justified by the company’s risks or whether it points to potential mispricing, the full valuation breakdown of this P/E relationship is the next logical step. This is covered in detail through the See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-earnings of 25.7x (UNDERVALUED) However, Lepu Biopharma still carries key risks, including uncertainty around late stage trial outcomes and the possibility that oncology competition could pressure future pricing power. Find out about the key risks to this Lepu Biopharma narrative. Next Steps Seeing both risks and rewards around Lepu Biopharma, do you want to move beyond headlines and sentiment and weigh the trade off yourself? For a balanced snapshot of what the market is cautious about and what it is optimistic on, review the 1 key reward and 1 important warning sign Looking for more investment ideas beyond Lepu Biopharma? If Lepu Biopharma has sharpened your focus on opportunities, do not stop here, broaden your watchlist so you are not relying on a single stock story.  Target potential value opportunities by reviewing the 211 high quality undervalued stocks that currently line up with solid fundamentals and measured expectations. Strengthen your defensive side by scanning the 295 resilient stocks with low risk scores that may better suit a cautious approach to volatility. Spot future contenders early by working through the screener containing 500 high quality undiscovered gems before they are widely followed.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649633957","isCrawlerRequest":true}